An analysis of the relationship of triglyceride glucose index with diffuse large B-cell lymphoma prognosis: a retrospective study.

Front Endocrinol (Lausanne)

Department of Hematology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.

Published: May 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Objective: Diffuse large B-cell lymphoma (DLBCL) as among the most common lymphomas is associated with insulin resistance (IR). The triglyceride-glucose (TyG) index, generally considered a surrogate marker for IR, has an uncertain prognostic value in DLBCL.

Methods: We conducted a retrospective analysis of DLBCL patients who received R-CHOP therapy at the Second Affiliated Hospital of Nanchang University from January 2011 to December 2023. Univariate and multivariate Cox regression analyses were performed to identify independent prognostic factors for overall survival (OS). Boruta algorithm was employed to strengthen the robustness of our analysis. Restricted cubic spline (RCS) analysis was used to explore the potential nonlinear relationship between the TyG index and OS. Subgroup analyses were conducted to assess the prognostic value of the TyG index across different patient subgroups. Finally, a nomogram model based on the TyG index was developed, and its predictive performance was evaluated using the area under the receiver operating characteristic curve (AUROC), calibration curves, and decision curve analysis (DCA).

Results: A total of 186 DLBCL patients were included in this study. Univariate and multivariate Cox regression analyses identified the TyG index, Age, ECOG performance status, Ann Arbor stage, and lactate dehydrogenase levels as independent prognostic factors for DLBCL. The Boruta algorithm confirmed these variables as the most important prognostic factors. Kaplan-Meier analysis revealed significantly poorer OS in the high TyG index group. RCS analysis demonstrated a non-linear relationship between the TyG index and OS. Subgroup analyses further validated the TyG index as a significant prognostic factor across various patient subgroups. The TyG-based nomogram model outperformed the conventional International Prognostic Index (IPI), with AUROCs of 0.878, 0.809, and 0.867 for 1-year, 3-year, and 5-year OS, respectively. Calibration curves showed good agreement between the nomogram predictions and actual outcomes, and DCA highlighted the high clinical utility of the model.

Conclusion: The TyG index is an independent prognostic factor in DLBCL patients, and the TyG-based nomogram model provides enhanced predictive accuracy compared to the IPI. Its simplicity and low cost make it a valuable tool for routine clinical prognostic assessment in DLBCL patients.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12066310PMC
http://dx.doi.org/10.3389/fendo.2025.1573986DOI Listing

Publication Analysis

Top Keywords

dlbcl patients
16
independent prognostic
12
prognostic factors
12
nomogram model
12
tyg
9
prognostic
9
diffuse large
8
large b-cell
8
b-cell lymphoma
8
univariate multivariate
8

Similar Publications

An international prognostic index to predict the early chemoimmunotherapy failure of diffuse large B-cell lymphoma.

Ann Hematol

September 2025

Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

 Approximately 30-40% of diffuse large B-cell lymphoma (DLBCL) patients will develop relapse/refractory disease, who may benefit from novel therapies, such as CAR-T cell therapy. Thus, accurate identification of individuals at high risk of early chemoimmunotherapy failure (ECF) is crucial. Methods.

View Article and Find Full Text PDF

Background: Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the treatment landscape for relapsed or refractory non-Hodgkin lymphoma, achieving a 5-year overall survival rate of 40-50%. However, relapse remains a major challenge, especially due to CD19-negative clones. Epcoritamab, a bispecific antibody targeting CD20 and CD3, offers a potential solution for post-CAR-T relapse; however, clinical data in this setting remain limited, particularly in Japan.

View Article and Find Full Text PDF

Diffuse large B-cell lymphoma (DLBCL) is a highly aggressive type of non-Hodgkin lymphoma. Accurate evaluation of treatment response is essential for effective management. This case report discusses the potential role of ⁶⁸Ga-Pentixafor positron emission tomography (PET)/computed tomography (CT) in comparison to F-fluorodeoxyglucose PET/CT for assessing treatment response in a patient with DLBCL.

View Article and Find Full Text PDF

Primary bladder diffuse large B-cell lymphoma: A rare case report.

Int J Surg Case Rep

September 2025

Department of Urology, The Second Affiliated Hospital, Kunming Medical University, Yunnan Province, China. Electronic address:

Introduction: Diffuse large B-cell lymphoma (DLBCL), a common subtype of non-Hodgkin lymphoma (NHL), originates primarily from lymph nodes, with a small proportion arising extranodally in sites such as the gastrointestinal tract and central nervous system. Given the general absence of lymphoid tissue in the bladder, primary bladder DLBCL is exceptionally rare.

Case Presentation: This case report describes an 83-year-old male patient with a bladder mass, initially suspected as cystitis glandularis, ultimately diagnosed via pathological examination as DLBCL.

View Article and Find Full Text PDF

Introduction And Importance: Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma, yet primary renal involvement is rare, constituting less than 1 % of renal malignancies. A case of non-germinal center B-cell-like (non-GCB) DLBCL with BCL-6 positivity is particularly unique. Conventionally, BCL-6 is linked to germinal center B-cell-like (GCB) subtypes.

View Article and Find Full Text PDF